Last reviewed · How we verify
NCT02631642
A Study of HMPL-689 in Healthy Volunteers
Phase 1 trial testing HMPL-689 in Healthy Volunteers in 48 participants. Completed in 28 February 2017.
26 October 2016
Quick facts
| Lead sponsor | Hutchison Medipharma Limited |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | health services research |
| Enrollment | 48 |
| Start date | 23 March 2016 |
| Primary completion | 26 October 2016 |
| Estimated completion | 28 February 2017 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- HMPL-689 — full drug profile →
- HMPL-689 placebo
Conditions studied
- Healthy Volunteers — all drugs for Healthy Volunteers →
Sponsor
Hutchison Medipharma Limited — full company profile →
Who can join
Adults 18 to 45, male only, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the safety and tolerability of a single dose of HMPL-689 in healthy volunteers To determine the pharmacokinetic profile of single oral doses of HMPL-689 in healthy volunteers
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02631642
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HMPL-689
Trials testing the same drug.
- NCT05713110 — A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma · Phase 2 · completed
- NCT04849351 — Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma · Phase 2 · completed
- NCT03786926 — Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas · Phase 1 · terminated
- NCT03128164 — A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed · Phase 1 · completed
Other recruiting trials for Healthy Volunteers
Currently open trials in the same condition.
- NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
- NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
- NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
- NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
- NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting
Other Hutchison Medipharma Limited trials
Trials by the same sponsor.
- NCT05509699 — Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer · Phase 2 · completed
- NCT05318820 — A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manuf · EARLY_PHASE1 · completed
- NCT05277454 — Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT · Phase 1 · unknown
- NCT05015608 — Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification · Phase 3 · active not recruiting
- NCT05029635 — Phase III Study on HMPL-523 for Treatment of ITP · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02631642 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hutchison Medipharma Limited
- Last refreshed: 17 August 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02631642.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing